Page last updated: 2024-10-30

metformin and Cancer of Pancreas

metformin has been researched along with Cancer of Pancreas in 182 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
"In people with metformin-treated diabetes, to evaluate the risk of acute pancreatitis, pancreatic cancer and other diseases of the pancreas post second-line anti-hyperglycaemic agent initiation."7.91Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. ( Atherton, J; Green, JB; Montvida, O; Paul, SK, 2019)
"Lymphoma and pancreatic cancer patients with type 2 diabetes were sorted into an experimental (metformin) group and a control (nonmetformin) group."7.91Metformin Associated With Increased Survival in Type 2 Diabetes Patients With Pancreatic Cancer and Lymphoma. ( Solomon, SS; Vacheron, A; Wynn, A; Zuber, J, 2019)
"We evaluated the relationship between liraglutide and acute pancreatitis or pancreatic cancer in an ongoing post-marketing safety assessment programme."7.80A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. ( Chan, KA; Funch, D; Gydesen, H; Major-Pedersen, A; Tornøe, K, 2014)
" Since improvement of β-cell viability is a promising anti-diabetic strategy, the protective effect of metformin, a known insulin sensitizer was studied in rat insulinoma cells."7.80Metformin attenuates palmitate-induced endoplasmic reticulum stress, serine phosphorylation of IRS-1 and apoptosis in rat insulinoma cells. ( Csala, M; Kéri, G; Kokas, M; Mandl, J; Simon-Szabó, L, 2014)
"Metformin and aspirin have been explored as two emerging cancer chemoprevention agents for different types of cancers, including pancreatic cancer."6.50Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. ( DiPaola, RS; Tan, XL; Yang, CS; Yue, W, 2014)
"Obesity has been linked to a higher risk of pancreatic cancer."5.91Metformin inhibits neutrophil extracellular traps-promoted pancreatic carcinogenesis in obese mice. ( Dai, S; Gao, H; Gao, Y; Jiang, K; Li, M; Lu, Z; Miao, Y; Wang, G; Yin, L; Zhang, J; Zhang, K, 2023)
"Metformin use was not associated with overall survival in the complete analyses (HR = 1."5.56Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus. ( Carson, KR; Chang, SH; Drake, BF; Luo, S; Sanfilippo, KM; Thomas, TS; Toriola, AT, 2020)
"Metformin was associated with increased PFS of patients receiving somatostatin analogues and in those receiving everolimus, with or without somatostatin analogues."5.48Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. ( Antonuzzo, L; Aroldi, F; Bajetta, E; Berardi, R; Bongiovanni, A; Brighi, N; Brizzi, MP; Buzzoni, R; Campana, D; Carnaghi, C; Catena, L; Cauchi, C; Cavalcoli, F; Cingarlini, S; Colao, A; Concas, L; Davì, MV; de Braud, F; De Divitiis, C; Delle Fave, G; Di Costanzo, F; Di Maio, M; Duro, M; Ermacora, P; Faggiano, A; Fazio, N; Femia, D; Fontana, A; Garattini, SK; Giacomelli, L; Giuffrida, D; Ibrahim, T; La Salvia, A; Lo Russo, G; Marconcini, R; Massironi, S; Mazzaferro, V; Milione, M; Ortolani, S; Panzuto, F; Perfetti, V; Prinzi, N; Puliafito, I; Pusceddu, S; Razzore, P; Ricci, S; Rinzivillo, M; Spada, F; Tafuto, S; Torniai, M; Vernieri, C; Zaniboni, A, 2018)
"Metformin treatment itself conferred better OS in comparison within DM patients (HR 0."5.43The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. ( Bang, YJ; Choi, Y; Han, SW; Im, SA; Kim, TY; Lee, KH; Oh, DY, 2016)
" In this article, we discuss the potential correlation between glycemic status, administration of antiglycemic treatments, such as metformin or insulin, and prognosis of pancreatic neuroendocrine tumors patients treated with everolimus and octreotide, on the basis of existing evidence and our experience."4.93Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. ( Buzzoni, R; Concas, L; de Braud, F; Femia, D; Formisano, B; Giacomelli, L; Leuzzi, L; Marceglia, S; Mazzaferro, V; Milione, M; Pusceddu, S; Vernieri, C, 2016)
" We performed a systematic review and meta-analysis evaluating the effect of metformin, sulfonylureas (SUs), thiazolidinediones (TZDs), and insulin on the risk of PaC in patients with diabetes mellitus (DM)."4.89Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. ( Chari, ST; McWilliams, RR; Murad, MH; Singh, AG; Singh, PP; Singh, S, 2013)
"In people with metformin-treated diabetes, to evaluate the risk of acute pancreatitis, pancreatic cancer and other diseases of the pancreas post second-line anti-hyperglycaemic agent initiation."3.91Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. ( Atherton, J; Green, JB; Montvida, O; Paul, SK, 2019)
"Lymphoma and pancreatic cancer patients with type 2 diabetes were sorted into an experimental (metformin) group and a control (nonmetformin) group."3.91Metformin Associated With Increased Survival in Type 2 Diabetes Patients With Pancreatic Cancer and Lymphoma. ( Solomon, SS; Vacheron, A; Wynn, A; Zuber, J, 2019)
"Metformin inhibited pancreatic cancer initiation, suppressed chronic pancreatitis-induced tumorigenesis, and showed promising therapeutic effect in PDAC."3.85Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. ( Cao, J; Chen, K; Cheng, L; Duan, W; Gao, L; Jiang, Z; Lei, M; Li, J; Ma, Q; Qian, W; Sun, L; Yan, B; Zhou, C, 2017)
"Metformin treatment is associated with a decreased risk and better prognosis of pancreatic cancer (PC) in patients with type 2 diabetes, but the mechanism of metformin's PC growth inhibition in the context of a prediabetic state is unknown."3.81Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms. ( Cifarelli, V; Devlin, KL; Dunlap, SM; Huang, J; Hursting, SD; Kaaks, R; Lashinger, LM; Pollak, MN, 2015)
"We explored if known risk factors for pancreatic cancer such as type II diabetes and chronic inflammation, influence the pathophysiology of an established primary tumor in the pancreas and if administration of metformin has an impact on tumor growth."3.81Impact of diabetes type II and chronic inflammation on pancreatic cancer. ( Albert, AC; Amme, J; Bürtin, F; Partecke, LI; Radecke, T; Vollmar, B; Zechner, D, 2015)
"We evaluated the relationship between liraglutide and acute pancreatitis or pancreatic cancer in an ongoing post-marketing safety assessment programme."3.80A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. ( Chan, KA; Funch, D; Gydesen, H; Major-Pedersen, A; Tornøe, K, 2014)
" Since improvement of β-cell viability is a promising anti-diabetic strategy, the protective effect of metformin, a known insulin sensitizer was studied in rat insulinoma cells."3.80Metformin attenuates palmitate-induced endoplasmic reticulum stress, serine phosphorylation of IRS-1 and apoptosis in rat insulinoma cells. ( Csala, M; Kéri, G; Kokas, M; Mandl, J; Simon-Szabó, L, 2014)
" Here, we show that treatment of pancreatic ductal adenocarcinoma (PDAC) cells (PANC-1, MiaPaCa-2) with the isoquinoline alkaloid berberine (0."3.80Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. ( Eibl, G; Ming, M; Rozengurt, E; Sinnett-Smith, J; Soares, HP; Wang, J; Young, SH, 2014)
"Metformin is a biguanide, widely used as a first‑line oral drug in treating type 2 diabetes."3.01Research progress on the therapeutic effect and mechanism of metformin for lung cancer (Review). ( Han, P; Liu, Q; Sun, K; Xiang, J; Zhou, J, 2023)
" The recommended dose of metformin combined with nivolumab is determined in part 1."2.87Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors. ( Fujiwara, T; Hotta, K; Kiura, K; Kozuki, T; Kubo, T; Ninomiya, T; Okada, H; Toyooka, S; Udono, H, 2018)
"In 2020, GLOBOCAN reported that pancreatic cancer accounts for 4."2.82Pharmacological Modulation of Apoptosis and Autophagy in Pancreatic Cancer Treatment. ( Islam, MK; Lian, HK; Lim, JCW; Sagineedu, SR; Selvarajoo, N; Stanslas, J, 2022)
"Metformin dose was escalated from 500 mg (in the first week) to 1000 mg twice daily in the second week."2.80Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. ( Beeker, A; Kordes, S; Mathôt, RA; Pollak, MN; Punt, CJ; Richel, DJ; Weterman, MJ; Wilmink, JW; Zwinderman, AH, 2015)
"At the time of diagnosis, almost 80% of pancreatic cancer patients present with new-onset type 2 diabetes (T2D) or impaired glucose tolerance."2.79Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion. ( Andersson, R; Karnevi, E; Rosendahl, AH, 2014)
"Metformin and BBR both activate AMP-activated protein kinase (AMPK) which is a key mediator of glucose metabolism."2.61Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. ( Abrams, SL; Akula, SM; Bueno-Silva, B; Candido, S; Cervello, M; Follo, MY; Gizak, A; Lertpiriyapong, K; Libra, M; Lin, HL; Lombardi, P; Mao, W; Martelli, AM; Matias de Alencar, S; McCubrey, JA; Montalto, G; Murata, RM; Rakus, D; Ramazzotti, G; Ratti, S; Rosalen, PL; Steelman, LS, 2019)
"Metformin use was associated with better overall survival among pancreatic cancer patients (meta-HR = 0."2.58Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis. ( Graber, JM; Lin, Y; Lu, SE; Lu-Yao, G; Tan, XL, 2018)
"Metformin is a widely used antidiabetic drug, and there is evidence among diabetic patients that metformin is a chemopreventive agent against multiple cancers."2.58Metformin-induced anticancer activities: recent insights. ( Karki, K; Nair, V; Safe, S, 2018)
"Pancreatic cancer is a highly lethal disease with a poor prognosis while metformin has been associated with a decreased risk of pancreatic cancer."2.55Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis. ( Li, B; Li, D; Li, YY; Liu, FR; Liu, YH; Wang, Q; Xu, C; Yao, Y; Zhang, MC; Zhou, PT, 2017)
"Metformin is a cornerstone in the treatment of diabetes mellitus type 2."2.53Metformin and pancreatic cancer: Is there a role? ( De Souza, A; Khawaja, KI; Masud, F; Saif, MW, 2016)
"Metformin use was associated with improved survival outcomes in patients with resected pancreatic cancer, but the difference was not statistically significant."2.53Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature. ( Ambe, CM; Chen, L; Fulp, J; Mahipal, A; Malafa, MP, 2016)
"We stress on the need for a better stratification of patients and a more rigorous planning of clinical trials not only focusing on classical parameters but also on potential predictive biomarkers (AMPK, mTOR, HIF-1α, IGF-1R) and metformin dosage for positive outcome."2.53Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification. ( Bhaw-Luximon, A; Jhurry, D, 2016)
"Survival from pancreatic cancer remains poor."2.53The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer. ( Amin, S; Boffetta, P; Lucas, AL, 2016)
"However, the function of aspirin use in pancreatic cancer largely remains unknown."2.53Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. ( Dai, JJ; Gu, DN; Huang, Q; Jiang, MJ; Tian, L, 2016)
"Metformin and aspirin have been explored as two emerging cancer chemoprevention agents for different types of cancers, including pancreatic cancer."2.50Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. ( DiPaola, RS; Tan, XL; Yang, CS; Yue, W, 2014)
"Clinicians and patients with type 2 diabetes enjoy an expanding list of medications to improve glycemic control."2.50Systematic reviews to ascertain the safety of diabetes medications. ( Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH, 2014)
"However, its influence on pancreatic cancer was controversial."2.50Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. ( Jiang, GL; Lai, ST; Ma, NY; Ren, ZG; Wang, Z; Xie, L; Zhao, JD; Zhu, J, 2014)
"Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined."2.50Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014)
"Long-standing type 1 diabetes and type 2 diabetes increase the risk for this malignancy, but the cancer can also induce pancreatogenic, or type 3c, diabetes as well."2.49Diabetes and cancer: placing the association in perspective. ( Andersen, DK, 2013)
"Diabetes or impaired glucose tolerance is present in more than 2/3rd of pancreatic cancer patients."2.48Diabetes and pancreatic cancer. ( Chari, ST; Muniraj, T, 2012)
"Type 3 diabetes mellitus is an effect, and therefore a harbinger, of pancreatic cancer in at least 30% of patients."2.47Diabetes and pancreatic cancer: chicken or egg? ( Andersen, DK; Elahi, D; Magruder, JT, 2011)
"Hepatic insulin resistance is characteristic of T3cDM and is caused by deficiencies of both insulin and pancreatic polypeptide."2.47Pancreatogenic diabetes: special considerations for management. ( Andersen, DK; Cui, Y, 2011)
"Obesity has been linked to a higher risk of pancreatic cancer."1.91Metformin inhibits neutrophil extracellular traps-promoted pancreatic carcinogenesis in obese mice. ( Dai, S; Gao, H; Gao, Y; Jiang, K; Li, M; Lu, Z; Miao, Y; Wang, G; Yin, L; Zhang, J; Zhang, K, 2023)
"The association between metformin and pancreatic cancer (PC) was explored using a WCE model within the framework of discrete-time Cox regression."1.91Reverse causation biases weighted cumulative exposure model estimates, but can be investigated in sensitivity analyses. ( Agay, N; Dankner, R; Freedman, LS; Murad, H; Olmer, L, 2023)
"Inactivation of Numb promotes the pancreatic cancer radio-resistance through hyperglycemic memory and metformin could suppress the radio-resistance by activating Numb in vitro and in vivo."1.72Numb/Notch/PLK1 signaling pathway mediated hyperglycemic memory in pancreatic cancer cell radioresistance and the therapeutic effects of metformin. ( Fang, C; Liu, C; Xia, J; Zhu, D, 2022)
"MM10 altered the OCR in prostate cancer cells."1.72EPR Investigations to Study the Impact of Mito-Metformin on the Mitochondrial Function of Prostate Cancer Cells. ( d'Hose, D; Gallez, B; Hardy, M; Jordan, BF; Mathieu, B; Mignion, L; Ouari, O; Sonveaux, P, 2022)
"Metformin is a commonly prescribed antidiabetic drug that demonstrated a potent immune modulator effect and antitumor response."1.72Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model. ( Abdelmoneim, M; Aboalela, MA; Bustos-Villalobos, I; Eissa, IR; Kasuya, H; Kodera, Y; Matsumura, S; Naoe, Y; Sibal, PA; Tanaka, M, 2022)
"KRas is frequently mutated in pancreatic cancers."1.62GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. ( Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS, 2021)
"The prognosis of pancreatic cancer is poor and new treatment strategies are urgently needed."1.62Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway. ( Andreassen, BK; Botteri, E; Bouche, G; Pantziarka, P; Sloan, EK; Støer, NC, 2021)
"Metformin use was not associated with overall survival in the complete analyses (HR = 1."1.56Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus. ( Carson, KR; Chang, SH; Drake, BF; Luo, S; Sanfilippo, KM; Thomas, TS; Toriola, AT, 2020)
"Metformin is an anti-hypoglycemic drug that appears to have anticancer effects."1.56Metformin Inhibits Proliferation and Tumor Growth of QGP-1 Pancreatic Neuroendocrine Tumor Cells by Inducing Cell Cycle Arrest and Apoptosis. ( Fujihara, S; Fujita, K; Fujita, N; Iwama, H; Kamada, H; Kato, K; Kobara, H; Kobayashi, K; Masaki, T; Morishita, A; Namima, D; Tsutsui, K; Yamana, H, 2020)
"Metformin has plausible direct and indirect anti-cancer properties against pancreatic adenocarcinoma cells."1.56An observational study to justify and plan a future phase III randomized controlled trial of metformin in improving overall survival in patients with inoperable pancreatic cancer without liver metastases. ( Broadhurst, PJ; Hart, AR, 2020)
"With human pancreatic cancer cell line PANC-1 as the study object, different concentrations of metformin were added for intervention."1.56Metformin reduces pancreatic cancer cell proliferation and increases apoptosis through MTOR signaling pathway and its dose-effect relationship. ( Jin, F; Wang, R; Zhao, HW; Zhao, JQ; Zhou, N, 2020)
"Type 2 diabetes mellitus is associated with pNET metastasis and not an independent risk factor for poor prognosis in pNETs."1.56Diabetes Is Associated With the Metastasis of Pancreatic Neuroendocrine Tumors. ( Cheng, H; Fan, K; Fan, Z; Gong, Y; Huang, Q; Jin, K; Liu, C; Luo, G; Ni, Q; Yang, C; Yu, X, 2020)
"Metformin is a drug used in the treatment of type 2 diabetes."1.56Metformin inhibits TGF‑β1‑induced epithelial‑mesenchymal transition and liver metastasis of pancreatic cancer cells. ( Endo, Y; Hirai, Y; Inoue, K; Ishikawa, T; Itoh, Y; Kamada, K; Matsumura, S; Mizushima, K; Naito, Y; Oka, K; Okayama, T; Ota, T; Sakamoto, N; Takagi, T; Uchiyama, K; Yoshida, J, 2020)
"The GEM-resistant human pancreatic cancer PANC-1/GEM cell line was established, and the proliferation ability of PANC-1 and PANC-1/GEM cell lines was detected using the Cell Counting Kit-8 (CCK-8), which was then detected by flow cytometry after they were labeled by Ki67."1.51Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway. ( Chen, XD; Qiao, ZG; Tang, JM; Wu, XY; Yao, XM; Zhou, HY, 2019)
"Gemcitabine (GEM) has become the standard chemotherapy for PDAC; however, acquired resistance to GEM is a major challenge."1.51Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma. ( Kitagawa, Y; Suzuki, K; Suzuki, Y; Takeuchi, O, 2019)
"Metformin promotes a survival benefit in individuals with PPDM but not PCRD."1.51Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer-Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study. ( Cho, J; Goodarzi, MO; Pandol, SJ; Petrov, MS; Scragg, R, 2019)
"Metformin is a very frequently prescribed drug used to treat type II diabetes."1.48Metformin influences drug sensitivity in pancreatic cancer cells. ( Abrams, SL; Candido, S; Cervello, M; Cocco, L; Follo, MY; Gizak, A; Lertpiriyapong, K; Libra, M; Lombardi, P; Martelli, AM; McCubrey, JA; Montalto, G; Murata, RM; Rakus, D; Ratti, S; Rosalen, PL; Steelman, L; Suh, PG, 2018)
"In this study, we evaluated in pancreatic cancer cells metformin, which blocks oxidative phosphorylation, in combination with α-cyano-4-hydroxycinnamate, which has been reported to inhibit the export of lactate from the cytosol."1.48α-cyano-4-hydroxycinnamate impairs pancreatic cancer cells by stimulating the p38 signaling pathway. ( Kerndl, H; Kumstel, S; Schönrogge, M; Vollmar, B; Zechner, D; Zhang, X, 2018)
"Metformin was associated with increased PFS of patients receiving somatostatin analogues and in those receiving everolimus, with or without somatostatin analogues."1.48Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. ( Antonuzzo, L; Aroldi, F; Bajetta, E; Berardi, R; Bongiovanni, A; Brighi, N; Brizzi, MP; Buzzoni, R; Campana, D; Carnaghi, C; Catena, L; Cauchi, C; Cavalcoli, F; Cingarlini, S; Colao, A; Concas, L; Davì, MV; de Braud, F; De Divitiis, C; Delle Fave, G; Di Costanzo, F; Di Maio, M; Duro, M; Ermacora, P; Faggiano, A; Fazio, N; Femia, D; Fontana, A; Garattini, SK; Giacomelli, L; Giuffrida, D; Ibrahim, T; La Salvia, A; Lo Russo, G; Marconcini, R; Massironi, S; Mazzaferro, V; Milione, M; Ortolani, S; Panzuto, F; Perfetti, V; Prinzi, N; Puliafito, I; Pusceddu, S; Razzore, P; Ricci, S; Rinzivillo, M; Spada, F; Tafuto, S; Torniai, M; Vernieri, C; Zaniboni, A, 2018)
"In this study, the human pancreatic cancer cell line MiaPaca-2 was incubated with liraglutide and/or metformin."1.48Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells. ( Hong, T; Ke, J; Liu, J; Lu, R; Tian, Q; Wei, R; Yang, J; Yu, F; Zhang, J, 2018)
"Treatment with metformin also suppressed tumor growth, invasion and EMT in LSL‑KrasG12D/+, Trp53fl/+and Pdx1‑Cre (KPC) transgenic mice that harbor spontaneous pancreatic cancer."1.48Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling. ( Cao, J; Chen, K; Cheng, L; Duan, W; Li, J; Li, X; Ma, J; Ma, Q; Qian, W; Qin, T; Xiao, Y; Zhou, C, 2018)
"Hypoglycemia is associated with local invasion and angiogenesis, whereas hyperglycemia promotes metastatic colonization."1.48Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma. ( Akkan, J; Benitz, S; Bruns, P; Ceyhan, GO; Cheng, T; Friess, H; Hofmann, T; Huang, P; Jäger, C; Jastroch, M; Jian, Z; Kleeff, J; Kleigrewe, K; Kong, B; Lamp, D; Maeritz, N; Michalski, CW; Nie, S; Raulefs, S; Shen, S; Shi, K; Steiger, K; Zhang, Z; Zou, X, 2018)
" However, at typical antidiabetic doses the bioavailability of metformin is presumably too low to exert antitumor effects."1.46Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, Antiproliferative Effects and Future EPR Studies. ( Cheng, G; Dwinell, MB; Hardy, M; Kalyanaraman, B; Ouari, O; Sikora, A; Zielonka, J, 2017)
"Metformin treatment itself conferred better OS in comparison within DM patients (HR 0."1.43The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. ( Bang, YJ; Choi, Y; Han, SW; Im, SA; Kim, TY; Lee, KH; Oh, DY, 2016)
"Metformin use was also associated with better OS (P = 0."1.43Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer. ( Anderson, EM; Chang, DT; Koong, AC; Kozak, MM; Norton, JA; Pai, JS; Poultsides, GA; Visser, BC; von Eyben, R, 2016)
"We used the human pancreatic cancer cell lines Panc1, PK1 and PK9 to study the effects of metformin on human pancreatic cancer cells."1.43The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin. ( Fujihara, S; Fujimori, T; Iwama, H; Kamada, H; Kato, K; Kobara, H; Kobayashi, K; Masaki, T; Yamashita, T, 2016)
"Aspc1, Bxpc3 and Panc1 pancreatic cancer cells were cultured in stem cell culture medium (serum-free Dulbecco's modified Eagle medium/Nutrient Mixture F-12 containing basic fibroblast growth factor, epidermal growth factor, B27 and insulin) for 5 days and it was found that all the pancreatic cancer cells aggregated into spheres and expressed pancreatic cancer stem cell surface markers."1.43Bulk pancreatic cancer cells can convert into cancer stem cells(CSCs) in vitro and 2 compounds can target these CSCs. ( Ben, Q; Du, Y; Gao, J; Gong, Y; He, X; Huang, L; Jin, J; Li, Z; Man, X; Ning, X; Wu, H; Xu, M, 2016)
"Although obesity is associated with increased systemic levels of placental growth factor (PlGF), the role of PlGF in obesity-induced tumor progression is not known."1.43PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. ( Ancukiewicz, M; Babykutty, S; Batista, A; Carmeliet, P; Chin, SM; Duda, DG; Fukumura, D; Hato, T; Hoffmman, U; Incio, J; Jain, RK; Jung, K; Khachatryan, A; Krop, IE; Ligibel, JA; McManus, DT; Puchner, SB; Rahbari, NN; Schlett, CL; Shibuya, M; Soares, R; Suboj, P; Tam, J; Vardam, TD, 2016)
"Metformin (Met) is an approved antidiabetic drug currently being explored for repurposing in cancer treatment based on recent evidence of its apparent chemopreventive properties."1.43Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells. ( Barrios, CS; Boyle, K; Cheng, G; Dwinell, MB; Hardy, M; Johnson, BD; Kalyanaraman, B; Lopez, M; McAllister, D; Ouari, O; Weber, JJ; Zielonka, J, 2016)
"Metformin use was identified in 456 patients (13."1.43Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer. ( Canner, J; Cerullo, M; Chen, SY; Gani, F; Pawlik, TM, 2016)
"Metformin is a commonly prescribed biguanide oral hypoglycemic used for the treatment of type II DM."1.43Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis. ( Amin, S; Aronson, A; Boffetta, P; Lin, J; Lucas, AL; Mhango, G; Wisnivesky, J, 2016)
" The present study assessed the ability of MET, alone or in combination with gemcitabine (GEM), to inhibit the growth of the human CFPAC‑1 pancreatic cancer cell line in vitro and in vivo."1.43Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo. ( He, Z; Jia, Z; Shi, Y; Xu, C, 2016)
"Pancreatic cancer is one of the hardest-to-treat types of neoplastic diseases."1.43Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer. ( Bezawork-Geleta, A; Boukalova, S; Cerny, J; Dong, L; Drahota, Z; Ezrova, Z; Neuzil, J; Pecinova, A; Stursa, J; Werner, L, 2016)
"Metformin has been associated with reduced risk of certain cancers, including PC, in some observational clinical studies."1.42Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study. ( Bracci, PM; Holly, EA; Ko, AH; Walker, EJ, 2015)
"Metformin was found to be a useful sensitising agent towards GEM treatment following gain of chemoresistance."1.42Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action. ( Baron, B; Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Wang, Y, 2015)
"Metformin may inhibit pancreatic tumorigenesis by modulating multiple molecular targets in inflammatory pathways."1.42Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling. ( Bamlet, WR; Bhattacharyya, KK; Dutta, SK; Mukhopadhyay, D; Oberg, AL; Petersen, GM; Rabe, KG; Smyrk, TC; Tan, XL; Wang, E, 2015)
"Metformin is a widely used drug for type-2 diabetes, and is also known as a promising candidate anti-cancer agent from recent studies in vitro and in vivo."1.42Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells. ( Horinaka, M; Sakai, T; Sowa, Y; Tanaka, R; Tomosugi, M, 2015)
"Metformin and aspirin have been studied extensively as cancer preventive or therapeutic agents."1.42Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. ( Carpizo, D; DiPaola, RS; Huang, H; Lin, Y; Tan, XL; Xu, Q; Yang, CS; Yue, W; Zheng, X, 2015)
"Metformin and aspirin have been studied extensively as cancer preventative and therapeutic agents."1.42Transcriptomic analysis of pancreatic cancer cells in response to metformin and aspirin: an implication of synergy. ( DiPaola, RS; Lin, Y; Tan, XL; Wang, T; Xu, Q; Yang, CS; Yue, W; Zachariah, E, 2015)
"The association of pancreatic cancer and diabetes mellitus is explored in our study."1.42Combination of Anti-Diabetic Drug Metformin and Boswellic Acid Nanoparticles: A Novel Strategy for Pancreatic Cancer Therapy. ( Kamath, CR; Lakshmanan, VK; Nair, RS; Nair, SV; Snima, KS, 2015)
"The prognosis of pancreatic cancer remains dismal, with little advance in chemotherapy because of its high frequency of chemoresistance."1.42Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling. ( Chai, X; Chu, H; Gou, S; Meng, Y; Shi, P; Yang, X, 2015)
"Associations between type 2 diabetes, anti-diabetic medications and pancreatic cancer are controversial."1.42New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer. ( Bexelius, TS; García Rodríguez, LA; González-Pérez, A; Lagergren, J; Lu, Y; Malgerud, L; Martín-Pérez, M, 2015)
"Metformin is a widely used glucose-lowering drug."1.42Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages. ( Babykutty, S; Chen, I; Chin, SM; Deshpande, V; Fukumura, D; Hato, T; Incio, J; Jain, RK; Liu, H; Suboj, P; Vardam-Kaur, T, 2015)
"Metformin is a target therapy that increases median overall survival but is not a radiation sensitizer in patients with pancreatic cancer who present with diabetes."1.40Diabetes and pancreatic cancer. ( De Souza, AL; Saif, MW, 2014)
"Metformin use has previously been associated with decreased cancer risk."1.40Metformin suppresses sonic hedgehog expression in pancreatic cancer cells. ( Nakamura, M; Nakashima, H; Ogo, A; Yamaguchi, Y; Yamura, M, 2014)
"The most glycolytic pancreatic cancer cell line was exquisitely sensitive to 2-DG, whereas the least glycolytic pancreatic cancer cell was resistant to 2-DG."1.40Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. ( Cheng, G; Dwinell, MB; Kalyanaraman, B; McAllister, D; Tsai, S; Zielonka, J, 2014)
"In addition, we found that pancreatic cancer stem cell-like cells showed enhanced radiosensitization in a tumorsphere assay with a REF of 1."1.40Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway. ( Elbaz, HA; Fasih, A; Hüttemann, M; Konski, AA; Zielske, SP, 2014)
"Treatment with metformin or down-regulation of Sp TFs by RNAi also inhibits two major pro-oncogenic pathways in pancreatic cancer cells, namely mammalian target of rapamycin (mTOR) signaling and epidermal growth factor (EGFR)-dependent activation of Ras."1.40Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors. ( Abdelrahim, M; Abudayyeh, A; Basha, R; Nair, V; Rodrigues Hoffman, A; Safe, S; Sreevalsan, S, 2014)
"Metformin also inhibited the growth of pancreatic cancer xenografts when administered orally (2."1.39Metformin inhibits the growth of human pancreatic cancer xenografts. ( Eibl, G; Kisfalvi, K; Moro, A; Rozengurt, E; Sinnett-Smith, J, 2013)
"Up to 80% of pancreatic cancer patients present with either new-onset type 2 diabetes or impaired glucose tolerance at the time of diagnosis."1.39Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. ( Andersson, R; Karnevi, E; Rosendahl, AH; Said, K, 2013)
"Metformin is a drug widely used for the treatment of type II diabetes."1.39Low concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer action. ( Cui, P; Gou, S; Li, X; Liu, T; Shi, P; Wang, C, 2013)
"Metformin treatment alone or with sitagliptin decreased islet amyloid deposition to a similar extent vs untreated mice."1.39One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice. ( Aston-Mourney, K; Goldstein, LC; Hull, RL; Meier, DT; Samarasekera, T; Subramanian, SL; Zraika, S, 2013)
"Metformin is a widely used antidiabetic drug, and epidemiology studies for pancreatic and other cancers indicate that metformin exhibits both chemopreventive and chemotherapeutic activities."1.39Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. ( Abdelrahim, M; Basha, R; Jutooru, I; Nair, V; Pathi, S; Safe, S; Samudio, I; Sreevalsan, S, 2013)
"Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States, which is, in part, due to intrinsic (de novo) and extrinsic (acquired) resistance to conventional therapeutics, suggesting that innovative treatment strategies are required for overcoming therapeutic resistance to improve overall survival of patients."1.38Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. ( Ahmad, A; Ali, S; Azmi, AS; Banerjee, S; Bao, B; Kong, D; Li, Y; Sarkar, FH; Sarkar, SH; Thakur, S; Wang, Z, 2012)
"Type 2 diabetes mellitus is likely the third modifiable risk factor for pancreatic cancer after cigarette smoking and obesity."1.38Diabetes and pancreatic cancer. ( Li, D, 2012)
"Pancreatic cancer is a disease with a dismal prognosis and treatment options are limited."1.38A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells. ( Funakoshi, A; Ikeda, N; Kawanami, T; Takiguchi, S, 2012)
"Metformin use was significantly associated with longer survival in patients with nonmetastatic disease only."1.38Metformin use is associated with better survival of diabetic patients with pancreatic cancer. ( Abbruzzese, JL; Hassan, M; Li, D; Sadeghi, N; Yeung, SC, 2012)
"Metformin and rosiglitazone suppressed cancer cell growth and induced apoptosis."1.37The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth. ( Chen, J; Feng, YH; Gully, C; Lee, MH; Velazquez-Torres, G; Yeung, SC, 2011)
" The covariates included age, gender, other oral anti-hyperglycemic medication, Charlson comorbidity index (CCI) score and metformin exposure dosage and duration."1.37Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. ( Chang, YH; Hsu, CC; Huang, YC; Lee, MS; Tsai, HN; Wahlqvist, ML, 2011)
"Novel targets for pancreatic cancer therapy are urgently needed."1.36Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. ( Kisfalvi, K; Rozengurt, E; Sinnett-Smith, J, 2010)
"The human pancreatic cancer cell lines ASPC-1, BxPc-3, PANC-1 and SW1990 were exposed to metformin."1.35Metformin induces apoptosis of pancreatic cancer cells. ( Gao, J; Jin, ZD; Li, ZS; Wang, LW; Xu, GM; Zou, DW, 2008)
"Metformin use was associated with reduced risk, and insulin or insulin secretagogue use was associated with increased risk of pancreatic cancer in diabetic patients."1.35Antidiabetic therapies affect risk of pancreatic cancer. ( Abbruzzese, JL; Hassan, MM; Konopleva, M; Li, D; Yeung, SC, 2009)
"Metformin pretreatment completely abrogated insulin-induced potentiation of Ca(2+) signaling but did not interfere with the effect of GPCR agonists alone."1.35Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. ( Eibl, G; Kisfalvi, K; Rozengurt, E; Sinnett-Smith, J, 2009)

Research

Studies (182)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (2.20)29.6817
2010's138 (75.82)24.3611
2020's40 (21.98)2.80

Authors

AuthorsStudies
Xue, D1
Xu, Y1
Kyani, A1
Roy, J1
Dai, L1
Sun, D1
Neamati, N1
Shi, L1
Wen, J1
Zhang, W1
Meng, FD1
Wan, Y1
Wang, L1
Zhang, L2
Zhu, HY1
Zhang, X3
Ogihara, T1
Zhu, M2
Gantumur, D1
Li, Y5
Mizoi, K1
Kamioka, H1
Tsushima, Y1
Zhu, D1
Xia, J1
Liu, C2
Fang, C1
Selvarajoo, N1
Stanslas, J1
Islam, MK1
Sagineedu, SR1
Lian, HK1
Lim, JCW1
Gulla, A1
Andriusaityte, U1
Zdanys, GT1
Babonaite, E1
Strupas, K1
Kelly, H1
Kurita, Y1
Kobayashi, N1
Hara, K1
Mizuno, N1
Kuwahara, T1
Okuno, N1
Haba, S1
Tokuhisa, M1
Hasegawa, S1
Sato, T1
Hosono, K1
Kato, S1
Kessoku, T1
Endo, I1
Shimizu, Y1
Kubota, K1
Nakajima, A1
Ichikawa, Y1
Niwa, Y1
Zaccari, P1
Archibugi, L1
Belfiori, G1
Nista, E1
dell'Anna, G1
Crippa, S1
Schepis, T1
Tacelli, M1
Aleotti, F1
Petrone, MC1
Mariani, A1
Costamagna, G1
Gasbarrini, A1
Larghi, A1
Falconi, M2
Arcidiacono, PG1
Capurso, G1
d'Hose, D1
Mathieu, B1
Mignion, L1
Hardy, M3
Ouari, O3
Jordan, BF1
Sonveaux, P1
Gallez, B1
Scarton, L1
Jo, A1
Xie, Z1
O'Neal, LJ1
Munoz Pena, JM1
George, TJ1
Bian, J1
Han, P1
Zhou, J1
Xiang, J1
Liu, Q1
Sun, K1
Pretta, A2
Ziranu, P2
Giampieri, R2
Donisi, C2
Cimbro, E2
Spanu, D2
Lai, E2
Pecci, F2
Balconi, F2
Lupi, A2
Pozzari, M2
Persano, M2
Murgia, S2
Pusceddu, V2
Puzzoni, M2
Berardi, R3
Scartozzi, M2
Abdelmoneim, M2
Eissa, IR2
Aboalela, MA2
Naoe, Y2
Matsumura, S3
Sibal, PA2
Bustos-Villalobos, I2
Tanaka, M2
Kodera, Y2
Kasuya, H2
Nowicka, Z1
Matyjek, A1
Płoszka, K1
Łaszczych, M1
Fendler, W1
Hu, J1
Fan, HD1
Gong, JP1
Mao, QS1
Wang, G1
Gao, H1
Dai, S1
Li, M1
Gao, Y1
Yin, L1
Zhang, K1
Zhang, J2
Jiang, K1
Miao, Y1
Lu, Z1
Agay, N1
Dankner, R2
Murad, H1
Olmer, L1
Freedman, LS1
Hamano, K1
Akita, K1
Takeuchi, Y1
Suwa, T1
Takeda, J1
Dodo, S1
Toriola, AT1
Luo, S1
Thomas, TS1
Drake, BF1
Chang, SH1
Sanfilippo, KM1
Carson, KR1
Roth, J1
de Mestier, L1
Védie, AL1
Faron, M1
Cros, J1
Rebours, V1
Hentic, O1
Do Cao, C1
Bardet, P1
Lévy, P1
Sauvanet, A1
Ruszniewski, P1
Hammel, P1
Deschênes-Simard, X1
Rowell, MC1
Ferbeyre, G1
Zhou, HY1
Yao, XM1
Chen, XD1
Tang, JM1
Qiao, ZG1
Wu, XY1
Yamana, H1
Kato, K2
Kobara, H2
Fujihara, S2
Fujita, K1
Namima, D1
Fujita, N1
Kobayashi, K2
Kamada, H2
Morishita, A1
Tsutsui, K1
Iwama, H2
Masaki, T2
Wendt, EHU1
Schoenrogge, M1
Vollmar, B4
Zechner, D4
Han, H1
Hou, Y1
Chen, X2
Zhang, P1
Kang, M1
Jin, Q1
Ji, J1
Gao, M1
Broadhurst, PJ2
Hart, AR2
Vitali, E1
Boemi, I1
Piccini, S1
Tarantola, G1
Smiroldo, V1
Lavezzi, E1
Brambilla, T1
Zerbi, A1
Carnaghi, C2
Mantovani, G1
Spada, A1
Lania, AG1
Terasaki, F1
Sugiura, T1
Okamura, Y1
Ito, T1
Yamamoto, Y1
Ashida, R1
Ohgi, K1
Uesaka, K1
Alcalá, S1
Sancho, P5
Martinelli, P2
Navarro, D1
Pedrero, C1
Martín-Hijano, L1
Valle, S1
Earl, J1
Rodríguez-Serrano, M1
Ruiz-Cañas, L1
Rojas, K1
Carrato, A1
García-Bermejo, L1
Fernández-Moreno, MÁ1
Hermann, PC2
Sainz, B3
Zhao, HW1
Zhou, N1
Jin, F1
Wang, R1
Zhao, JQ1
Fan, Z1
Gong, Y2
Huang, Q2
Yang, C1
Cheng, H1
Jin, K1
Fan, K1
Ni, Q1
Yu, X2
Luo, G1
Yoshida, J1
Ishikawa, T1
Endo, Y1
Ota, T1
Mizushima, K1
Hirai, Y1
Oka, K1
Okayama, T1
Sakamoto, N1
Inoue, K1
Kamada, K1
Uchiyama, K1
Takagi, T1
Naito, Y1
Itoh, Y1
Ma, M1
Ma, C2
Li, P1
Ping, F1
Li, W2
Xu, L2
Zhang, H1
Sun, Q2
Wang, C3
Zhang, T1
Liao, Q1
Dai, M1
Guo, J2
Yang, X2
Tan, W1
Lin, D1
Wu, C1
Zhao, Y1
Liu, SH2
Yu, J2
Creeden, JF1
Sutton, JM1
Markowiak, S1
Sanchez, R2
Nemunaitis, J2
Kalinoski, A1
Zhang, JT1
Damoiseaux, R1
Erhardt, P1
Brunicardi, FC2
Shi, YQ1
Zhou, XC1
Du, P1
Yin, MY1
Chen, WJ1
Xu, CF1
Farag, MM1
Abd El Malak, NS1
Yehia, SA1
Ahmed, MA1
Eyres, M1
Lanfredini, S1
Xu, H1
Burns, A1
Blake, A1
Willenbrock, F1
Goldin, R1
Hughes, D1
Hughes, S1
Thapa, A1
Vavoulis, D1
Hubert, A1
D'Costa, Z1
Sabbagh, A1
Abraham, AG1
Blancher, C1
Jones, S1
Verrill, C1
Silva, M1
Soonawalla, Z1
Maughan, T1
Schuh, A1
Mukherjee, S1
O'Neill, E1
Abrams, SL3
Akula, SM2
Meher, AK1
Steelman, LS2
Gizak, A3
Duda, P1
Rakus, D3
Martelli, AM3
Ratti, S3
Cocco, L2
Montalto, G3
Cervello, M3
Ruvolo, P1
Libra, M3
Falzone, L1
Candido, S3
McCubrey, JA3
Eibl, G5
Rozengurt, E9
Støer, NC1
Bouche, G1
Pantziarka, P1
Sloan, EK1
Andreassen, BK1
Botteri, E1
Wu, BU1
Graber, JM2
Lu, SE2
Lin, Y4
Lu-Yao, G2
Tan, XL6
Kalyanaraman, B3
Cheng, G3
Sikora, A1
Zielonka, J3
Dwinell, MB3
Zhou, PT1
Li, B1
Liu, FR1
Zhang, MC1
Wang, Q1
Li, YY1
Xu, C2
Liu, YH1
Yao, Y1
Li, D5
E, JY1
Rotter, D1
Petersen, GM3
Demissie, K1
Li, X4
Li, T1
Liu, Z1
Gou, S3
Chen, K4
Qian, W3
Jiang, Z3
Cheng, L3
Li, J6
Sun, L2
Zhou, C4
Gao, L1
Lei, M1
Yan, B2
Cao, J3
Duan, W4
Ma, Q4
Li, L1
Zhang, G1
Wang, Y2
Chen, H1
Kong, R1
Pan, S1
Sun, B1
Safe, S3
Nair, V3
Karki, K1
Goldenberg, JM1
Cárdenas-Rodríguez, J1
Pagel, MD1
Sun, H1
Zheng, C1
Gao, J3
Fu, Q1
Hu, N1
Shao, X1
Zhou, Y1
Xiong, J1
Nie, K1
Zhou, H1
Shen, L1
Fang, H1
Lyu, J1
Wirunsawanya, K1
Jaruvongvanich, V1
Upala, S1
Steelman, L1
Lertpiriyapong, K2
Follo, MY2
Murata, RM2
Rosalen, PL2
Lombardi, P2
Suh, PG1
Song, L1
Chang, R1
Peng, X1
Xu, X1
Zhan, X1
Zhan, L1
Schönrogge, M2
Kerndl, H1
Kumstel, S2
Chang, HH1
Moro, A2
Chou, CEN1
Dawson, DW1
French, S1
Schmidt, AI1
Sinnett-Smith, J8
Hao, F1
Hines, OJ1
Pusceddu, S2
Vernieri, C2
Di Maio, M1
Marconcini, R1
Spada, F1
Massironi, S1
Ibrahim, T1
Brizzi, MP1
Campana, D1
Faggiano, A1
Giuffrida, D1
Rinzivillo, M1
Cingarlini, S1
Aroldi, F1
Antonuzzo, L1
Catena, L1
De Divitiis, C1
Ermacora, P1
Perfetti, V1
Fontana, A1
Razzore, P1
Davì, MV1
Cauchi, C1
Duro, M1
Ricci, S1
Fazio, N1
Cavalcoli, F1
Bongiovanni, A1
La Salvia, A1
Brighi, N1
Colao, A1
Puliafito, I1
Panzuto, F1
Ortolani, S1
Zaniboni, A1
Di Costanzo, F1
Torniai, M1
Bajetta, E1
Tafuto, S1
Garattini, SK1
Femia, D2
Prinzi, N1
Concas, L2
Lo Russo, G1
Milione, M2
Giacomelli, L2
Buzzoni, R2
Delle Fave, G1
Mazzaferro, V2
de Braud, F2
Lu, R1
Yang, J1
Wei, R1
Ke, J1
Tian, Q1
Yu, F1
Liu, J2
Hong, T1
Lee, DY1
Yu, JH1
Park, S1
Han, K1
Kim, NH2
Yoo, HJ1
Choi, KM1
Baik, SH1
Seo, JA1
Qin, T1
Xiao, Y1
Ma, J2
Kubo, T1
Ninomiya, T1
Hotta, K1
Kozuki, T1
Toyooka, S1
Okada, H1
Fujiwara, T1
Udono, H1
Kiura, K1
Wan, G1
Sun, X1
Li, F1
Wang, X3
Li, C1
Li, H1
Cao, F1
Tseng, CH1
Jian, Z1
Cheng, T1
Zhang, Z1
Raulefs, S1
Shi, K1
Steiger, K1
Maeritz, N1
Kleigrewe, K1
Hofmann, T1
Benitz, S1
Bruns, P1
Lamp, D1
Jastroch, M1
Akkan, J1
Jäger, C1
Huang, P1
Nie, S1
Shen, S1
Zou, X1
Ceyhan, GO1
Michalski, CW1
Friess, H1
Kleeff, J1
Kong, B1
Montvida, O1
Green, JB1
Atherton, J1
Paul, SK1
Suzuki, K1
Takeuchi, O1
Suzuki, Y1
Kitagawa, Y1
Wei, M1
Liu, Y4
Bi, Y1
Zhang, ZJ1
Lai, SW1
Tsai, CH1
Lin, CL1
Liao, KF1
Ramazzotti, G1
Bueno-Silva, B1
Matias de Alencar, S1
Mao, W1
Lin, HL1
Cho, J1
Scragg, R1
Pandol, SJ1
Goodarzi, MO1
Petrov, MS1
Wynn, A1
Vacheron, A1
Zuber, J1
Solomon, SS1
Andersen, DK4
Soares, HP2
Ni, Y1
Kisfalvi, K5
Karnevi, E2
Said, K1
Andersson, R2
Rosendahl, AH2
Cui, P1
Shi, P2
Liu, T1
Aston-Mourney, K1
Subramanian, SL1
Zraika, S1
Samarasekera, T1
Meier, DT1
Goldstein, LC1
Hull, RL1
Pathi, S1
Jutooru, I1
Sreevalsan, S2
Basha, R2
Abdelrahim, M2
Samudio, I1
El-Jurdi, NH1
Saif, MW5
Hwang, AL1
Haynes, K1
Hwang, WT1
Yang, YX2
Funch, D1
Gydesen, H1
Tornøe, K1
Major-Pedersen, A1
Chan, KA1
Lonardo, E2
Cioffi, M2
Sanchez-Ripoll, Y1
Trabulo, SM1
Dorado, J1
Balic, A1
Hidalgo, M1
Heeschen, C4
Yue, W3
Yang, CS3
DiPaola, RS3
Gionfriddo, MR1
Morey-Vargas, OL1
Brito, JP1
Leppin, AL1
Murad, MH2
Montori, VM1
De Souza, AL1
Nakamura, M1
Ogo, A1
Yamura, M1
Yamaguchi, Y1
Nakashima, H1
Snima, KS3
Jayakumar, R2
Unnikrishnan, AG1
Nair, SV2
Lakshmanan, VK3
Wang, Z4
Lai, ST2
Xie, L1
Zhao, JD2
Ma, NY2
Zhu, J1
Ren, ZG1
Jiang, GL2
McAllister, D2
Tsai, S1
Simon-Szabó, L1
Kokas, M1
Mandl, J1
Kéri, G1
Csala, M1
Fasih, A1
Elbaz, HA1
Hüttemann, M1
Konski, AA1
Zielske, SP1
Yoon, JW1
Jung, HS1
Jang, JY1
Kim, MJ1
Kim, JH2
Ohn, JH1
Lee, HM1
Kim, HC1
Lee, KB1
Choi, SA1
Kim, SW1
Park, KS1
Burney, S1
Khawaja, KI2
Masud, F2
Kaddis, N1
Walker, EJ1
Ko, AH1
Holly, EA1
Bracci, PM1
Cañamero, M1
Madriles, F1
Michl, P1
Gress, T1
de Pascual, R1
Gandia, L1
Guerra, C1
Barbacid, M1
Wagner, M1
Vieira, CR1
Aicher, A1
Real, FX1
Abudayyeh, A1
Rodrigues Hoffman, A1
Herrigel, DJ1
Moss, RA1
Ming, M1
Wang, J1
Young, SH1
Cifarelli, V1
Lashinger, LM1
Devlin, KL1
Dunlap, SM1
Huang, J1
Kaaks, R1
Pollak, MN2
Hursting, SD1
Choi, Y1
Kim, TY2
Oh, DY1
Lee, KH1
Han, SW1
Im, SA1
Bang, YJ1
Baron, B1
Maehara, S1
Maehara, Y1
Kuramitsu, Y1
Nakamura, K1
Bhattacharyya, KK1
Dutta, SK1
Bamlet, WR2
Rabe, KG1
Wang, E1
Smyrk, TC1
Oberg, AL2
Mukhopadhyay, D1
Radecke, T2
Amme, J1
Bürtin, F2
Albert, AC2
Partecke, LI1
Tanaka, R1
Tomosugi, M1
Horinaka, M1
Sowa, Y1
Sakai, T1
Lin, CM1
Huang, HL1
Chu, FY1
Fan, HC1
Chen, HA1
Chu, DM1
Wu, LW1
Wang, CC1
Chen, WL1
Lin, SH1
Ho, SY1
Zhang, JW1
Zheng, X1
Xu, Q4
Carpizo, D1
Huang, H1
Aung, KL1
Moore, MJ1
Kordes, S1
Zwinderman, AH1
Mathôt, RA1
Weterman, MJ1
Beeker, A1
Punt, CJ1
Richel, DJ1
Wilmink, JW1
Crusz, S1
Wang, T1
Zachariah, E1
Nair, RS1
Kamath, CR1
Deng, Y2
Wei, DP1
Burgos-Ramos, E1
Tavera, A1
Bou Kheir, T1
Jagust, P1
Schoenhals, M1
Barneda, D1
Sellers, K1
Campos-Olivas, R1
Graña, O1
Viera, CR1
Yuneva, M1
Chai, X1
Chu, H1
Meng, Y1
Chao, DT1
Shah, NH1
Zeh, HJ1
Bahary, N1
Whitcomb, DC1
Brand, RE1
Reni, M1
Dugnani, E1
Cereda, S1
Belli, C1
Balzano, G1
Nicoletti, R1
Liberati, D1
Pasquale, V1
Scavini, M1
Maggiora, P1
Sordi, V1
Lampasona, V1
Ceraulo, D1
Di Terlizzi, G1
Doglioni, C1
Piemonti, L1
Kozak, MM1
Anderson, EM1
von Eyben, R1
Pai, JS1
Poultsides, GA1
Visser, BC1
Norton, JA1
Koong, AC1
Chang, DT1
Lu, Y1
García Rodríguez, LA1
Malgerud, L1
González-Pérez, A1
Martín-Pérez, M1
Lagergren, J1
Bexelius, TS1
Rustgi, AK1
Incio, J2
Suboj, P2
Chin, SM2
Vardam-Kaur, T1
Liu, H1
Hato, T2
Babykutty, S2
Chen, I1
Deshpande, V1
Jain, RK2
Fukumura, D2
Zhou, G1
Wang, A1
Wu, J1
Ricordi, C1
Yamashita, T1
Fujimori, T1
Ning, X1
Du, Y1
Ben, Q1
Huang, L2
He, X1
Wu, H1
Man, X1
Jin, J1
Xu, M1
Li, Z1
De Souza, A1
Lipner, MB1
Marayati, R1
Raftery, L1
O'Neil, BH1
Yeh, JJ1
Lee, SH1
Yoon, SH1
Lee, HS1
Chung, MJ1
Park, JY1
Park, SW1
Song, SY1
Chung, JB1
Bang, S1
Tam, J1
Rahbari, NN1
McManus, DT1
Vardam, TD1
Batista, A1
Jung, K1
Khachatryan, A1
Ligibel, JA1
Krop, IE1
Puchner, SB1
Schlett, CL1
Hoffmman, U1
Ancukiewicz, M1
Shibuya, M1
Carmeliet, P1
Soares, R1
Duda, DG1
Marceglia, S1
Leuzzi, L1
Formisano, B1
Ambe, CM1
Mahipal, A1
Fulp, J1
Chen, L1
Malafa, MP1
Chaiteerakij, R1
Chaffee, KG1
Zhen, DB1
Burch, PA1
Leof, ER1
Roberts, LR1
Stiefelhagen, P1
Bhaw-Luximon, A1
Jhurry, D1
Lopez, M1
Boyle, K1
Barrios, CS1
Weber, JJ1
Johnson, BD1
Cerullo, M1
Gani, F1
Chen, SY1
Canner, J1
Pawlik, TM1
Elmaci, İ1
Altinoz, MA1
Amin, S2
Mhango, G1
Lin, J1
Aronson, A1
Wisnivesky, J1
Boffetta, P2
Lucas, AL2
Graffunder, J1
Shih, HY1
Müller, S1
Jaster, R1
Shi, Y1
He, Z1
Jia, Z1
Elgogary, A1
Poore, B1
Alt, J1
Zimmermann, SC1
Zhao, L1
Fu, J1
Chen, B1
Xia, S1
Neisser, M1
Nguyen, C1
Lee, R1
Park, JK1
Reyes, J1
Hartung, T1
Rojas, C1
Rais, R1
Tsukamoto, T1
Semenza, GL1
Hanes, J1
Slusher, BS1
Le, A1
Jiang, MJ1
Dai, JJ1
Gu, DN1
Tian, L1
Zhang, Q1
Kang, L1
Yang, Y1
Yang, L2
Zu, L1
Shen, Y1
Qi, Z1
Boukalova, S1
Stursa, J1
Werner, L1
Ezrova, Z1
Cerny, J1
Bezawork-Geleta, A1
Pecinova, A1
Dong, L1
Drahota, Z1
Neuzil, J1
Lei, J1
Han, L1
Wu, Z1
Wang, F1
Wu, E1
Ma, Z1
Halbrook, CJ1
Lyssiotis, CA1
Chang, VH1
Tsai, YC1
Tsai, YL1
Peng, SL1
Chen, SL1
Chang, TM1
Yu, WC1
Ch'ang, HJ1
Frouws, MA1
Sibinga Mulder, BG1
Bastiaannet, E1
Zanders, MMJ1
van Herk-Sukel, MPP1
de Leede, EM1
Bonsing, BA1
Mieog, JSD1
Van de Velde, CJH1
Liefers, GJ1
Wang, LW1
Li, ZS1
Zou, DW1
Jin, ZD1
Xu, GM1
Yeung, SC3
Hassan, MM1
Konopleva, M1
Abbruzzese, JL3
Nicolucci, A1
Feng, YH1
Velazquez-Torres, G1
Gully, C1
Chen, J1
Lee, MH1
Lee, MS1
Hsu, CC1
Wahlqvist, ML1
Tsai, HN1
Chang, YH1
Huang, YC1
Magruder, JT1
Elahi, D1
Cui, Y2
Ringel, J1
Lerch, MM1
Mayerle, J1
Bao, B1
Ali, S2
Ahmad, A1
Azmi, AS1
Sarkar, SH1
Banerjee, S1
Kong, D1
Thakur, S1
Sarkar, FH2
Kawanami, T1
Takiguchi, S1
Ikeda, N1
Funakoshi, A1
Yuan, Y1
Qiao, M1
Zhang, Y1
Bodmer, M1
Becker, C1
Meier, C1
Jick, SS1
Meier, CR1
Bednar, F1
Simeone, DM1
Pollak, M1
Sadeghi, N1
Hassan, M1
Brower, V1
Flaherty, AM1
Kui, R1
Haq, S1
Mohammad, R1
Muniraj, T1
Chari, ST2
Singh, S1
Singh, PP1
Singh, AG1
McWilliams, RR1
Schneider, MB1
Matsuzaki, H1
Haorah, J1
Ulrich, A1
Standop, J1
Ding, XZ1
Adrian, TE1
Pour, PM1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Melanoma, breAst or Lung Cancer Patients With Brain Metastases: the Phase II OPTIMAL Study[NCT04001725]Phase 2110 participants (Anticipated)Interventional2019-10-15Recruiting
An Open-Label Single-Arm Phase Ⅱ Study to Evaluate Efficacy and Safety of Sintilimab Combined With Metformin Hydrochloride in Patients With Advanced Non-small Cell Lung Cancer Refractory to First-Line Treatment[NCT03874000]Phase 243 participants (Anticipated)Interventional2019-03-08Recruiting
The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547]Phase 220 participants (Anticipated)Interventional2019-01-31Not yet recruiting
Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug in Partially Pancreatectomized Patients Due to Benign Pancreatic Neoplasm.[NCT01922492]28 participants (Actual)Interventional2008-05-31Active, not recruiting
A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gemcitabine, Erlotinib and Metformin in Patients With Locally Advanced and Metastatic Pancreatic Cancer[NCT01210911]Phase 2120 participants (Actual)Interventional2010-08-31Completed
Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806]Phase 415 participants (Anticipated)Interventional2022-10-10Active, not recruiting
Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024]Phase 250 participants (Anticipated)Interventional2015-03-31Active, not recruiting
Metformin Pharmacology in Human Cancers[NCT03477162]Early Phase 118 participants (Actual)Interventional2018-05-15Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Concentration of Metformin in Adipose Tissue

To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery

Interventionng/g (Median)
Metformin70

Concentration of Metformin in Plasma.

To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery

Interventionng/mL (Median)
Metformin450

Concentration of Metformin in Tumor-adjacent Normal Tissue

To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery

Interventionng/g (Median)
Metformin749

Concentration of Metformin in Whole Blood.

To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery

Interventionng/mL (Median)
Metformin514

Lung Tumor Tissue Concentration of Metformin

To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery

Interventionng/g (Median)
Metformin1290

Reviews

40 reviews available for metformin and Cancer of Pancreas

ArticleYear
Effect of metformin on
    The British journal of radiology, 2022, Feb-01, Volume: 95, Issue:1130

    Topics: Animals; Breast Neoplasms; Carcinoma, Hepatocellular; Colonic Neoplasms; Diabetes Mellitus, Type 2;

2022
Pharmacological Modulation of Apoptosis and Autophagy in Pancreatic Cancer Treatment.
    Mini reviews in medicinal chemistry, 2022, Volume: 22, Issue:20

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; ErbB

2022
Pharmacological Modulation of Apoptosis and Autophagy in Pancreatic Cancer Treatment.
    Mini reviews in medicinal chemistry, 2022, Volume: 22, Issue:20

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; ErbB

2022
Pharmacological Modulation of Apoptosis and Autophagy in Pancreatic Cancer Treatment.
    Mini reviews in medicinal chemistry, 2022, Volume: 22, Issue:20

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; ErbB

2022
Pharmacological Modulation of Apoptosis and Autophagy in Pancreatic Cancer Treatment.
    Mini reviews in medicinal chemistry, 2022, Volume: 22, Issue:20

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; ErbB

2022
The Impact of Epithelial-Mesenchymal Transition and Metformin on Pancreatic Cancer Chemoresistance: A Pathway towards Individualized Therapy.
    Medicina (Kaunas, Lithuania), 2022, 03-23, Volume: 58, Issue:4

    Topics: Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Human

2022
The Impact of Epithelial-Mesenchymal Transition and Metformin on Pancreatic Cancer Chemoresistance: A Pathway towards Individualized Therapy.
    Medicina (Kaunas, Lithuania), 2022, 03-23, Volume: 58, Issue:4

    Topics: Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Human

2022
The Impact of Epithelial-Mesenchymal Transition and Metformin on Pancreatic Cancer Chemoresistance: A Pathway towards Individualized Therapy.
    Medicina (Kaunas, Lithuania), 2022, 03-23, Volume: 58, Issue:4

    Topics: Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Human

2022
The Impact of Epithelial-Mesenchymal Transition and Metformin on Pancreatic Cancer Chemoresistance: A Pathway towards Individualized Therapy.
    Medicina (Kaunas, Lithuania), 2022, 03-23, Volume: 58, Issue:4

    Topics: Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Human

2022
Research progress on the therapeutic effect and mechanism of metformin for lung cancer (Review).
    Oncology reports, 2023, Volume: 49, Issue:1

    Topics: Aged; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin; Middle Aged

2023
Metanalyses on metformin's role in pancreatic cancer suffer from severe bias and low data quality - An umbrella review.
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2023, Volume: 23, Issue:2

    Topics: Data Accuracy; Humans; Metformin; Pancreatic Neoplasms; Retrospective Studies

2023
Metanalyses on metformin's role in pancreatic cancer suffer from severe bias and low data quality - An umbrella review.
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2023, Volume: 23, Issue:2

    Topics: Data Accuracy; Humans; Metformin; Pancreatic Neoplasms; Retrospective Studies

2023
Metanalyses on metformin's role in pancreatic cancer suffer from severe bias and low data quality - An umbrella review.
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2023, Volume: 23, Issue:2

    Topics: Data Accuracy; Humans; Metformin; Pancreatic Neoplasms; Retrospective Studies

2023
Metanalyses on metformin's role in pancreatic cancer suffer from severe bias and low data quality - An umbrella review.
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2023, Volume: 23, Issue:2

    Topics: Data Accuracy; Humans; Metformin; Pancreatic Neoplasms; Retrospective Studies

2023
The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis.
    BMC gastroenterology, 2023, Feb-24, Volume: 23, Issue:1

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pancreatic Neoplasms

2023
The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis.
    BMC gastroenterology, 2023, Feb-24, Volume: 23, Issue:1

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pancreatic Neoplasms

2023
The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis.
    BMC gastroenterology, 2023, Feb-24, Volume: 23, Issue:1

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pancreatic Neoplasms

2023
The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis.
    BMC gastroenterology, 2023, Feb-24, Volume: 23, Issue:1

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pancreatic Neoplasms

2023
More recent, better designed studies have weakened links between antidiabetes medications and cancer risk.
    Diabetic medicine : a journal of the British Diabetic Association, 2020, Volume: 37, Issue:2

    Topics: Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glycoside H

2020
Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes: A systematic review and meta-analysis.
    Medicine, 2020, Sep-11, Volume: 99, Issue:37

    Topics: Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male

2020
Metformin: review of epidemiology and mechanisms of action in pancreatic cancer.
    Cancer metastasis reviews, 2021, Volume: 40, Issue:3

    Topics: Carcinoma, Pancreatic Ductal; Humans; Hypoglycemic Agents; Metformin; Pancreas; Pancreatic Neoplasms

2021
Diabetes and pancreatic cancer: recent insights with implications for early diagnosis, treatment and prevention.
    Current opinion in gastroenterology, 2021, 09-01, Volume: 37, Issue:5

    Topics: Diabetes Mellitus, Type 2; Early Detection of Cancer; Humans; Hypoglycemic Agents; Metformin; Pancre

2021
Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis.
    Current medicinal chemistry, 2018, Volume: 25, Issue:22

    Topics: Databases, Factual; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Odds Ratio; P

2018
Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis.
    Oncotarget, 2017, Apr-11, Volume: 8, Issue:15

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pancreatic Neoplasms; Proportiona

2017
The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis.
    Scientific reports, 2017, 07-19, Volume: 7, Issue:1

    Topics: Humans; Metformin; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Publication Bias; Su

2017
Metformin-induced anticancer activities: recent insights.
    Biological chemistry, 2018, 03-28, Volume: 399, Issue:4

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans;

2018
Survival Benefits From Metformin Use in Pancreatic Cancer: A Systemic Review and Meta-analysis.
    Pancreas, 2018, Volume: 47, Issue:3

    Topics: Female; Humans; Hypoglycemic Agents; Male; Metformin; Outcome Assessment, Health Care; Pancreatic Ne

2018
Metformin as an Adjunctive Therapy for Pancreatic Cancer: A Review of the Literature on Its Potential Therapeutic Use.
    Digestive diseases and sciences, 2018, Volume: 63, Issue:11

    Topics: Carcinoma, Pancreatic Ductal; Humans; Hypoglycemic Agents; Metformin; Pancreatic Neoplasms; Proof of

2018
Survival Benefit of Metformin Adjuvant Treatment For Pancreatic Cancer Patients: a Systematic Review and Meta-Analysis.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 49, Issue:3

    Topics: Chemotherapy, Adjuvant; Databases, Factual; Disease-Free Survival; Humans; Metformin; Pancreatic Neo

2018
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells.
    Advances in biological regulation, 2019, Volume: 73

    Topics: AMP-Activated Protein Kinases; Berberine; Cell Proliferation; Humans; Metformin; Neoplasm Proteins;

2019
Diabetes and cancer: placing the association in perspective.
    Current opinion in endocrinology, diabetes, and obesity, 2013, Volume: 20, Issue:2

    Topics: Blood Glucose; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Diabetes Complications

2013
Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment.
    Cancer prevention research (Philadelphia, Pa.), 2014, Volume: 7, Issue:4

    Topics: AMP-Activated Protein Kinases; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Repositioning;

2014
Systematic reviews to ascertain the safety of diabetes medications.
    Current diabetes reports, 2014, Volume: 14, Issue:4

    Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractur

2014
Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Diabetes research and clinical practice, 2014, Volume: 106, Issue:1

    Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Pancreatic

2014
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
    Postgraduate medicine, 2014, Volume: 126, Issue:6

    Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp

2014
Metformin and pancreatic cancer: Is there a role?
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:2

    Topics: Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metform

2016
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
    Future oncology (London, England), 2016, Volume: 12, Issue:10

    Topics: Antineoplastic Agents; Comorbidity; Diabetes Mellitus; Everolimus; Humans; Hypoglycemic Agents; Metf

2016
Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature.
    PloS one, 2016, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Humans; Kaplan-Meier Estimate; Metformin; Pancreatic Neoplasms

2016
Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification.
    Journal of cancer research and clinical oncology, 2016, Volume: 142, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Humans; Metformin; Pancr

2016
A Metabolic Inhibitory Cocktail for Grave Cancers: Metformin, Pioglitazone and Lithium Combination in Treatment of Pancreatic Cancer and Glioblastoma Multiforme.
    Biochemical genetics, 2016, Volume: 54, Issue:5

    Topics: Brain Neoplasms; Cell Proliferation; Drug Therapy, Combination; Gene Expression Regulation, Neoplast

2016
The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer.
    Gut and liver, 2016, Sep-15, Volume: 10, Issue:5

    Topics: Adrenergic beta-Antagonists; Anticarcinogenic Agents; Antineoplastic Agents; Aspirin; Dipeptidyl-Pep

2016
Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials.
    Biochimica et biophysica acta, 2016, Volume: 1866, Issue:2

    Topics: Animals; Anticarcinogenic Agents; Aspirin; Cancer Pain; Humans; Metformin; Pancreatic Neoplasms

2016
Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer.
    Cancer cell, 2017, 01-09, Volume: 31, Issue:1

    Topics: Carcinoma, Pancreatic Ductal; Cellular Reprogramming; Fluorodeoxyglucose F18; Glucose; Glutamine; Hu

2017
Epidemiological aspects of neoplasms in diabetes.
    Acta diabetologica, 2010, Volume: 47, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Case-Control Studies; Cell Divis

2010
Diabetes and pancreatic cancer: chicken or egg?
    Pancreas, 2011, Volume: 40, Issue:3

    Topics: Biomarkers, Tumor; Case-Control Studies; Causality; Diabetes Complications; Diabetes Mellitus; Diabe

2011
Pancreatogenic diabetes: special considerations for management.
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2011, Volume: 11, Issue:3

    Topics: Administration, Oral; Animals; Diabetes Mellitus; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV In

2011
[Pancreatic diseases: update 2011].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:40

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Diabetes Mellitus; Diagnosis, D

2011
Diabetes and pancreatic cancer.
    Endocrine-related cancer, 2012, Volume: 19, Issue:5

    Topics: Animals; Antineoplastic Agents; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agen

2012
Management of diabetes and pancreatic cancer.
    Oncology nursing forum, 2012, Volume: 39, Issue:5

    Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2012
The complexities of epidemiology and prevention of gastrointestinal cancers.
    International journal of molecular sciences, 2012, Oct-01, Volume: 13, Issue:10

    Topics: Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Diabetes Complications; Folic Acid; Gastrointesti

2012
Diabetes and pancreatic cancer.
    Minerva gastroenterologica e dietologica, 2012, Volume: 58, Issue:4

    Topics: Age Factors; Body Mass Index; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Early Detection o

2012
Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
    The American journal of gastroenterology, 2013, Volume: 108, Issue:4

    Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin; Metformin; Pancreatic Neoplasms; Risk Asses

2013

Trials

5 trials available for metformin and Cancer of Pancreas

ArticleYear
Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors.
    Clinical lung cancer, 2018, Volume: 19, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Comb

2018
Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion.
    Immunology and cell biology, 2014, Volume: 92, Issue:6

    Topics: CD11c Antigen; Cell Line, Tumor; Coculture Techniques; Diabetes Mellitus, Type 2; Female; Glucose; H

2014
Improved Insulin Secretion by Autologous Islet Transplantation, Compared to Oral Antidiabetic Agents, After Distal Pancreatectomy.
    Cell transplantation, 2015, Volume: 24, Issue:8

    Topics: Adamantane; Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gly

2015
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:7

    Topics: Academic Medical Centers; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Pr

2015
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Mar-01, Volume: 22, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine;

2016

Other Studies

137 other studies available for metformin and Cancer of Pancreas

ArticleYear
Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors.
    Journal of medicinal chemistry, 2022, 01-13, Volume: 65, Issue:1

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Discover

2022
Combination therapy with interleukin-15 and metformin as a synergistic treatment for pancreatic cancer.
    European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:16

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line; Cell Line,

2021
Numb/Notch/PLK1 signaling pathway mediated hyperglycemic memory in pancreatic cancer cell radioresistance and the therapeutic effects of metformin.
    Cellular signalling, 2022, Volume: 93

    Topics: Animals; Membrane Proteins; Metformin; Nerve Tissue Proteins; Pancreatic Neoplasms; Receptors, Notch

2022
Numb/Notch/PLK1 signaling pathway mediated hyperglycemic memory in pancreatic cancer cell radioresistance and the therapeutic effects of metformin.
    Cellular signalling, 2022, Volume: 93

    Topics: Animals; Membrane Proteins; Metformin; Nerve Tissue Proteins; Pancreatic Neoplasms; Receptors, Notch

2022
Numb/Notch/PLK1 signaling pathway mediated hyperglycemic memory in pancreatic cancer cell radioresistance and the therapeutic effects of metformin.
    Cellular signalling, 2022, Volume: 93

    Topics: Animals; Membrane Proteins; Metformin; Nerve Tissue Proteins; Pancreatic Neoplasms; Receptors, Notch

2022
Numb/Notch/PLK1 signaling pathway mediated hyperglycemic memory in pancreatic cancer cell radioresistance and the therapeutic effects of metformin.
    Cellular signalling, 2022, Volume: 93

    Topics: Animals; Membrane Proteins; Metformin; Nerve Tissue Proteins; Pancreatic Neoplasms; Receptors, Notch

2022
Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms.
    Internal medicine (Tokyo, Japan), 2023, Jan-15, Volume: 62, Issue:2

    Topics: Aged; Everolimus; Humans; Metformin; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis

2023
Risk factors for the occurrence of ampullary tumors: A case-control study.
    United European gastroenterology journal, 2022, Volume: 10, Issue:7

    Topics: Adenoma; Ampulla of Vater; Aspirin; Carcinoma; Case-Control Studies; Common Bile Duct Neoplasms; Duo

2022
EPR Investigations to Study the Impact of Mito-Metformin on the Mitochondrial Function of Prostate Cancer Cells.
    Molecules (Basel, Switzerland), 2022, Sep-10, Volume: 27, Issue:18

    Topics: Antioxidants; Carbon; Cell Line, Tumor; Glutathione Disulfide; Humans; Male; Metformin; Mitochondria

2022
Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis.
    PloS one, 2022, Volume: 17, Issue:10

    Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Medicare; Metfor

2022
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2023
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2023
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
    Scientific reports, 2022, 12-13, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc

2022
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
    Scientific reports, 2022, 12-13, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc

2022
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
    Scientific reports, 2022, 12-13, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc

2022
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
    Scientific reports, 2022, 12-13, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc

2022
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
    Scientific reports, 2022, 12-13, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc

2022
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
    Scientific reports, 2022, 12-13, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc

2022
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
    Scientific reports, 2022, 12-13, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc

2022
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
    Scientific reports, 2022, 12-13, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc

2022
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
    Scientific reports, 2022, 12-13, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc

2022
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
    Scientific reports, 2022, 12-13, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc

2022
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
    Scientific reports, 2022, 12-13, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc

2022
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
    Scientific reports, 2022, 12-13, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc

2022
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
    Scientific reports, 2022, 12-13, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc

2022
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
    Scientific reports, 2022, 12-13, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc

2022
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
    Scientific reports, 2022, 12-13, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc

2022
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model.
    Scientific reports, 2022, 12-13, Volume: 12, Issue:1

    Topics: Animals; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Metformin; Mice; Oncolytic Virotherapy; Onc

2022
Metformin inhibits neutrophil extracellular traps-promoted pancreatic carcinogenesis in obese mice.
    Cancer letters, 2023, 05-28, Volume: 562

    Topics: Animals; Carcinogenesis; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Extracellular Traps; Metfo

2023
Reverse causation biases weighted cumulative exposure model estimates, but can be investigated in sensitivity analyses.
    Journal of clinical epidemiology, 2023, Volume: 161

    Topics: Bias; Causality; Diabetes Mellitus; Humans; Metformin; Pancreatic Neoplasms; Risk Factors

2023
Glucose-responsive Insulinoma with Insulin Hypersecretion Suppressed by Metformin.
    Internal medicine (Tokyo, Japan), 2019, Dec-15, Volume: 58, Issue:24

    Topics: Glucose Tolerance Test; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulinoma; Male; Metfor

2019
Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2020, Volume: 29, Issue:1

    Topics: Aged; Black or African American; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Comorbidity;

2020
The Postoperative Occurrence or Worsening of Diabetes Mellitus May Increase the Risk of Recurrence in Resected Pancreatic Neuroendocrine Tumors.
    Neuroendocrinology, 2020, Volume: 110, Issue:11-12

    Topics: Adult; Aged; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metfor

2020
Metformin turns off the metabolic switch of pancreatic cancer.
    Aging, 2019, 12-12, Volume: 11, Issue:23

    Topics: Cell Proliferation; Cellular Senescence; Gene Expression Regulation; Humans; Hypoglycemic Agents; Me

2019
Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway.
    European review for medical and pharmacological sciences, 2019, Volume: 23, Issue:23

    Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Ex

2019
Metformin Inhibits Proliferation and Tumor Growth of QGP-1 Pancreatic Neuroendocrine Tumor Cells by Inducing Cell Cycle Arrest and Apoptosis.
    Anticancer research, 2020, Volume: 40, Issue:1

    Topics: Apoptosis; Biomarkers; Carcinoma, Neuroendocrine; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Pro

2020
Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells.
    Anticancer research, 2020, Volume: 40, Issue:1

    Topics: Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship,

2020
Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy.
    Journal of the American Chemical Society, 2020, 03-11, Volume: 142, Issue:10

    Topics: Adenocarcinoma; Amino Acid Sequence; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; C

2020
An observational study to justify and plan a future phase III randomized controlled trial of metformin in improving overall survival in patients with inoperable pancreatic cancer without liver metastases.
    Journal of cancer research and clinical oncology, 2020, Volume: 146, Issue:5

    Topics: Aged; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Cross-Sectional Studies; Fe

2020
A novel insight into the anticancer mechanism of metformin in pancreatic neuroendocrine tumor cells.
    Molecular and cellular endocrinology, 2020, 06-01, Volume: 509

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tu

2020
Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus.
    Langenbeck's archives of surgery, 2020, Volume: 405, Issue:3

    Topics: Adult; Aged; Carcinoma, Pancreatic Ductal; Diabetes Complications; Female; Humans; Hypoglycemic Agen

2020
ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity.
    Nature communications, 2020, 05-29, Volume: 11, Issue:1

    Topics: Carcinoma, Pancreatic Ductal; Cell Line; Cell Plasticity; Cell Transformation, Neoplastic; Cytokines

2020
Metformin reduces pancreatic cancer cell proliferation and increases apoptosis through MTOR signaling pathway and its dose-effect relationship.
    European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screeni

2020
Diabetes Is Associated With the Metastasis of Pancreatic Neuroendocrine Tumors.
    Pancreas, 2020, Volume: 49, Issue:6

    Topics: China; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male;

2020
Metformin inhibits TGF‑β1‑induced epithelial‑mesenchymal transition and liver metastasis of pancreatic cancer cells.
    Oncology reports, 2020, Volume: 44, Issue:1

    Topics: Animals; Antigens, CD; Cadherins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Epithelial-Me

2020
Low glucose enhanced metformin's inhibitory effect on pancreatic cancer cells by suppressing glycolysis and inducing energy stress via up-regulation of miR-210-5p.
    Cell cycle (Georgetown, Tex.), 2020, Volume: 19, Issue:17

    Topics: Anaerobiosis; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Energ

2020
Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation.
    Protein & cell, 2021, Volume: 12, Issue:2

    Topics: Animals; Cell Line; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 4; Hum

2021
Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma.
    Cancer letters, 2020, 10-28, Volume: 491

    Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Digoxin; Drug Combinations; Drug Reposition

2020
Hyaluronic Acid Conjugated Metformin-Phospholipid Sonocomplex: A Biphasic Complexation Approach to Correct Hypoxic Tumour Microenvironment.
    International journal of nanomedicine, 2021, Volume: 16

    Topics: 1-Octanol; Animals; Cell Line, Tumor; Cell Proliferation; Glucose; Humans; Hyaluronic Acid; Hypoxia-

2021
TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.
    Gastroenterology, 2021, Volume: 161, Issue:2

    Topics: 5-Methylcytosine; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Biomarkers

2021
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
    Cells, 2021, 04-06, Volume: 10, Issue:4

    Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compound

2021
Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway.
    Acta oncologica (Stockholm, Sweden), 2021, Volume: 60, Issue:9

    Topics: Adenocarcinoma; Cohort Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; P

2021
Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, Antiproliferative Effects and Future EPR Studies.
    Cell biochemistry and biophysics, 2017, Volume: 75, Issue:3-4

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Electron Spin Resonance Spectroscopy; E

2017
Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2017, Volume: 26, Issue:8

    Topics: Adenocarcinoma; Aged; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors

2017
Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2017, Volume: 26, Issue:8

    Topics: Adenocarcinoma; Aged; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors

2017
Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2017, Volume: 26, Issue:8

    Topics: Adenocarcinoma; Aged; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors

2017
Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2017, Volume: 26, Issue:8

    Topics: Adenocarcinoma; Aged; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors

2017
Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer.
    Molecular cancer, 2017, 07-24, Volume: 16, Issue:1

    Topics: Animals; Carcinogenesis; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Disease Models, Animal; Di

2017
Crucial microRNAs and genes in metformin's anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis.
    Investigational new drugs, 2018, Volume: 36, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemi

2018
Preliminary Results that Assess Metformin Treatment in a Preclinical Model of Pancreatic Cancer Using Simultaneous [
    Molecular imaging and biology, 2018, Volume: 20, Issue:4

    Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Humans; Magnetic Reson

2018
Oncogenic HSP60 regulates mitochondrial oxidative phosphorylation to support Erk1/2 activation during pancreatic cancer cell growth.
    Cell death & disease, 2018, 02-07, Volume: 9, Issue:2

    Topics: Adenocarcinoma; Adenosine Triphosphate; Animals; Apoptosis; Carcinogenesis; Carcinoma, Pancreatic Du

2018
Metformin influences drug sensitivity in pancreatic cancer cells.
    Advances in biological regulation, 2018, Volume: 68

    Topics: Animals; Carcinoma, Pancreatic Ductal; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Metform

2018
Metformin influences drug sensitivity in pancreatic cancer cells.
    Advances in biological regulation, 2018, Volume: 68

    Topics: Animals; Carcinoma, Pancreatic Ductal; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Metform

2018
Metformin influences drug sensitivity in pancreatic cancer cells.
    Advances in biological regulation, 2018, Volume: 68

    Topics: Animals; Carcinoma, Pancreatic Ductal; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Metform

2018
Metformin influences drug sensitivity in pancreatic cancer cells.
    Advances in biological regulation, 2018, Volume: 68

    Topics: Animals; Carcinoma, Pancreatic Ductal; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Metform

2018
LKB1 obliterates Snail stability and inhibits pancreatic cancer metastasis in response to metformin treatment.
    Cancer science, 2018, Volume: 109, Issue:5

    Topics: AMP-Activated Protein Kinase Kinases; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell

2018
α-cyano-4-hydroxycinnamate impairs pancreatic cancer cells by stimulating the p38 signaling pathway.
    Cellular signalling, 2018, Volume: 47

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coumaric Acids; Hexokinase;

2018
Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model.
    Scientific reports, 2018, 04-12, Volume: 8, Issue:1

    Topics: Acyltransferases; Administration, Oral; Animals; Carcinogenesis; Carcinoma, Pancreatic Ductal; Chemo

2018
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
    Gastroenterology, 2018, Volume: 155, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Diabetes Mellitus, Type 2;

2018
Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.
    PloS one, 2018, Volume: 13, Issue:6

    Topics: AMP-Activated Protein Kinases; bcl-2-Associated X Protein; Caspase 3; Cell Cycle Checkpoints; Cell L

2018
The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea.
    Scientific reports, 2018, 06-26, Volume: 8, Issue:1

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglyc

2018
Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling.
    Oncology reports, 2018, Volume: 40, Issue:3

    Topics: Animals; Apoptosis; Autocrine Communication; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell M

2018
Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
    Life sciences, 2018, Sep-01, Volume: 208

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycyt

2018
Metformin and Pancreatic Cancer Risk in Patients With Type 2 Diabetes.
    Pancreas, 2018, Volume: 47, Issue:9

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Metformin; Pancreatic Neoplasms;

2018
Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma.
    Cellular and molecular gastroenterology and hepatology, 2018, Volume: 6, Issue:4

    Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Collagen Type VI; Core

2018
Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma.
    Cellular and molecular gastroenterology and hepatology, 2018, Volume: 6, Issue:4

    Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Collagen Type VI; Core

2018
Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma.
    Cellular and molecular gastroenterology and hepatology, 2018, Volume: 6, Issue:4

    Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Collagen Type VI; Core

2018
Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma.
    Cellular and molecular gastroenterology and hepatology, 2018, Volume: 6, Issue:4

    Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Collagen Type VI; Core

2018
Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
    Diabetic medicine : a journal of the British Diabetic Association, 2019, Volume: 36, Issue:4

    Topics: Acute Disease; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Co

2019
Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
    International journal of oncology, 2019, Volume: 54, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine

2019
Metformin and pancreatic cancer survival: Real effect or immortal time bias?
    International journal of cancer, 2019, 10-01, Volume: 145, Issue:7

    Topics: Bias; Databases, Bibliographic; Evidence-Based Medicine; Female; Humans; Male; Metformin; Pancreatic

2019
Association between pancreatic cancer and metformin use in patients with type 2 diabetes.
    Postgraduate medical journal, 2019, Volume: 95, Issue:1123

    Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Logistic Models; Metfo

2019
Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer-Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study.
    Diabetes care, 2019, Volume: 42, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyce

2019
Metformin Associated With Increased Survival in Type 2 Diabetes Patients With Pancreatic Cancer and Lymphoma.
    The American journal of the medical sciences, 2019, Volume: 358, Issue:3

    Topics: Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lymphoma; Male; Metformin; Mid

2019
Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Antibiotics, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Ext

2013
Metformin inhibits the growth of human pancreatic cancer xenografts.
    Pancreas, 2013, Volume: 42, Issue:5

    Topics: Administration, Oral; Animals; Blotting, Western; Body Weight; Cell Line, Tumor; Dose-Response Relat

2013
Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells.
    BMC cancer, 2013, May-10, Volume: 13

    Topics: AMP-Activated Protein Kinases; Analysis of Variance; Apoptosis; Cell Line, Tumor; Cell Proliferation

2013
Low concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer action.
    PloS one, 2013, Volume: 8, Issue:5

    Topics: AC133 Antigen; Antigens, CD; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response

2013
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
    American journal of physiology. Endocrinology and metabolism, 2013, Aug-15, Volume: 305, Issue:4

    Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; H

2013
Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors.
    Carcinogenesis, 2013, Volume: 34, Issue:12

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regula

2013
Diabetes and pancreatic cancer.
    JOP : Journal of the pancreas, 2013, Jul-10, Volume: 14, Issue:4

    Topics: Adenocarcinoma; Diabetes Mellitus; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Panc

2013
Metformin and survival in pancreatic cancer: a retrospective cohort study.
    Pancreas, 2013, Volume: 42, Issue:7

    Topics: Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Age

2013
A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:3

    Topics: Databases, Factual; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hyp

2014
Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease

2013
Diabetes and pancreatic cancer.
    JOP : Journal of the pancreas, 2014, Mar-10, Volume: 15, Issue:2

    Topics: Diabetes Complications; Early Diagnosis; Humans; Metformin; Pancreatic Neoplasms; Risk Factors; Surv

2014
Metformin suppresses sonic hedgehog expression in pancreatic cancer cells.
    Anticancer research, 2014, Volume: 34, Issue:4

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neop

2014
O-carboxymethyl chitosan nanoparticles for metformin delivery to pancreatic cancer cells.
    Carbohydrate polymers, 2012, Jul-01, Volume: 89, Issue:3

    Topics: Cell Line, Tumor; Chitosan; Drug Carriers; Hemolysis; Humans; Metformin; Microscopy, Electron, Scann

2012
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
    British journal of cancer, 2014, Jul-08, Volume: 111, Issue:1

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Proce

2014
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
    British journal of cancer, 2014, Jul-08, Volume: 111, Issue:1

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Proce

2014
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
    British journal of cancer, 2014, Jul-08, Volume: 111, Issue:1

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Proce

2014
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
    British journal of cancer, 2014, Jul-08, Volume: 111, Issue:1

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Proce

2014
Metformin attenuates palmitate-induced endoplasmic reticulum stress, serine phosphorylation of IRS-1 and apoptosis in rat insulinoma cells.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Animals; Apoptosis; Caspase 3; Cell Line, Tumor; Endoplasmic Reticulum Stress; Eukaryotic Initiation

2014
Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway.
    Radiation research, 2014, Volume: 182, Issue:1

    Topics: AMP-Activated Protein Kinases; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Repair;

2014
Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors.
    JOP : Journal of the pancreas, 2014, Jul-28, Volume: 15, Issue:4

    Topics: Adenocarcinoma; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Human

2014
Second-line treatment for pancreatic cancer.
    JOP : Journal of the pancreas, 2014, Jul-28, Volume: 15, Issue:4

    Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance,

2014
Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study.
    International journal of cancer, 2015, Mar-15, Volume: 136, Issue:6

    Topics: Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; L

2015
In vitro and in vivo biological evaluation of O-carboxymethyl chitosan encapsulated metformin nanoparticles for pancreatic cancer therapy.
    Pharmaceutical research, 2014, Volume: 31, Issue:12

    Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Movement; Chitosan; Colony-Formin

2014
Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Gastroenterology, 2014, Volume: 147, Issue:5

    Topics: Acinar Cells; alpha7 Nicotinic Acetylcholine Receptor; Animals; Carcinoma, Pancreatic Ductal; Cell D

2014
Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors.
    The Journal of biological chemistry, 2014, Oct-03, Volume: 289, Issue:40

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neopl

2014
Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors.
    The Journal of biological chemistry, 2014, Oct-03, Volume: 289, Issue:40

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neopl

2014
Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors.
    The Journal of biological chemistry, 2014, Oct-03, Volume: 289, Issue:40

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neopl

2014
Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors.
    The Journal of biological chemistry, 2014, Oct-03, Volume: 289, Issue:40

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neopl

2014
Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Acetyl-CoA Carboxylase; Adenocarcinoma; AMP-Activated Protein Kinases; Animals; Berberine; Carcinoma

2014
Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms.
    Diabetes, 2015, Volume: 64, Issue:5

    Topics: Animals; Body Weight; Cell Cycle; Diet, Diabetic; Energy Intake; Glucose Intolerance; Hypoglycemic A

2015
The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy.
    Cancer research and treatment, 2016, Volume: 48, Issue:1

    Topics: Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Pancreatic Neopla

2016
Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action.
    Anticancer research, 2015, Volume: 35, Issue:4

    Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Heat-Sh

2015
Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling.
    Pancreas, 2015, Volume: 44, Issue:4

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Drug Administration Schedule;

2015
Impact of diabetes type II and chronic inflammation on pancreatic cancer.
    BMC cancer, 2015, Feb-13, Volume: 15

    Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Cell Death; Cell Line, Tumor; Cell

2015
Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Line, T

2015
Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Adult; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus; Female; Glycoside Hydrolase Inhibito

2015
Metformin may improve the prognosis of patients with pancreatic cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:9

    Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Top

2015
Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2.
    Oncotarget, 2015, Aug-28, Volume: 6, Issue:25

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Aspirin; Bcl-2-Like Protei

2015
Metformin for pancreatic cancer.
    The Lancet. Oncology, 2015, Volume: 16, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Metformin; Pancreatic Neoplasm

2015
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies.
    Journal of visualized experiments : JoVE, 2015, Jun-20, Issue:100

    Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Female; Humans; Metformin; Mice; Mic

2015
Transcriptomic analysis of pancreatic cancer cells in response to metformin and aspirin: an implication of synergy.
    Scientific reports, 2015, Aug-21, Volume: 5

    Topics: Aspirin; Cell Line, Tumor; Down-Regulation; Drug Synergism; Gene Expression Profiling; Gene Expressi

2015
Combination of Anti-Diabetic Drug Metformin and Boswellic Acid Nanoparticles: A Novel Strategy for Pancreatic Cancer Therapy.
    Journal of biomedical nanotechnology, 2015, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Diffusion; Dose-Response Relationship, Dr

2015
Radiosensitization of metformin in pancreatic cancer cells via abrogating the G2 checkpoint and inhibiting DNA damage repair.
    Cancer letters, 2015, Dec-01, Volume: 369, Issue:1

    Topics: Apoptosis; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Chemoradiotherapy; Cyclin-Dep

2015
MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells.
    Cell metabolism, 2015, Oct-06, Volume: 22, Issue:4

    Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Drug Resistance, Neoplasm; Gene Library

2015
Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling.
    Scientific reports, 2015, Sep-22, Volume: 5

    Topics: AC133 Antigen; Animals; Antigens, CD; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug

2015
Increased Serum Insulin Exposure Does Not Affect Age or Stage of Pancreatic Adenocarcinoma Diagnosis in Patients With Diabetes Mellitus.
    Pancreas, 2016, Volume: 45, Issue:2

    Topics: Adenocarcinoma; Age of Onset; Aged; Alcohol Drinking; Body Mass Index; Cohort Studies; Diabetes Mell

2016
Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer.
    Pancreas, 2016, Volume: 45, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; California; Carcinoma, Pancreatic Ductal; Disease-Free Survival; Fem

2016
New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer.
    British journal of cancer, 2015, Dec-01, Volume: 113, Issue:11

    Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglyc

2015
Impact of Metformin on Advanced Pancreatic Cancer Survival: Too Little, Too Late?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Mar-01, Volume: 22, Issue:5

    Topics: Humans; Metformin; Pancreatic Neoplasms

2016
Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages.
    PloS one, 2015, Volume: 10, Issue:12

    Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Epithelial

2015
Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
    Current molecular medicine, 2016, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line; Cell Line, Tumor; Diabetes Mellitus, Type 2

2016
Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
    Current molecular medicine, 2016, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line; Cell Line, Tumor; Diabetes Mellitus, Type 2

2016
Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
    Current molecular medicine, 2016, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line; Cell Line, Tumor; Diabetes Mellitus, Type 2

2016
Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.
    Current molecular medicine, 2016, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line; Cell Line, Tumor; Diabetes Mellitus, Type 2

2016
The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin.
    Oncology reports, 2016, Volume: 35, Issue:3

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cyclin D1; ErbB Receptors; Gene Expression Regulation

2016
Bulk pancreatic cancer cells can convert into cancer stem cells(CSCs) in vitro and 2 compounds can target these CSCs.
    Cell cycle (Georgetown, Tex.), 2016, Volume: 15, Issue:3

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; beta Catenin; Cell Line, Tumor; Ce

2016
Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal

2016
Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; CA-19-9 Antigen; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyc

2016
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 06-15, Volume: 22, Issue:12

    Topics: Animals; Breast Neoplasms; Diet, High-Fat; Female; Glucose; Humans; Hypoglycemic Agents; Macrophages

2016
Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 06-01, Volume: 34, Issue:16

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Female; Humans; Male;

2016
[The risk is higher, but why?].
    MMW Fortschritte der Medizin, 2016, Mar-31, Volume: 158, Issue:6

    Topics: Carcinoma, Hepatocellular; Diabetes Complications; Humans; Liver Neoplasms; Metformin; Neoplasms; Pa

2016
Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells.
    Cancer research, 2016, 07-01, Volume: 76, Issue:13

    Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Proliferation;

2016
Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2016, Volume: 20, Issue:9

    Topics: Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Lymphatic Metastasis; Male; Metformin; Middl

2016
Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis.
    The American journal of gastroenterology, 2016, Volume: 111, Issue:9

    Topics: Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Comorbidity; Diabetes Mellitus, Type 2; Femal

2016
Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin.
    Oncotarget, 2016, Aug-30, Volume: 7, Issue:35

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cell Hypoxia

2016
Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin.
    Oncotarget, 2016, Aug-30, Volume: 7, Issue:35

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cell Hypoxia

2016
Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin.
    Oncotarget, 2016, Aug-30, Volume: 7, Issue:35

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cell Hypoxia

2016
Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin.
    Oncotarget, 2016, Aug-30, Volume: 7, Issue:35

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cell Hypoxia

2016
Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo.
    Molecular medicine reports, 2016, Volume: 14, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis;

2016
Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.
    Proceedings of the National Academy of Sciences of the United States of America, 2016, 09-06, Volume: 113, Issue:36

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetamides; Cell Line, Tumor; Glutam

2016
Metformin potentiates anti-tumor effect of resveratrol on pancreatic cancer by down-regulation of VEGF-B signaling pathway.
    Oncotarget, 2016, Dec-20, Volume: 7, Issue:51

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosi

2016
Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:12

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease M

2016
Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
    Cancer letters, 2017, 01-28, Volume: 385

    Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Che

2017
Krüpple-like factor 10 regulates radio-sensitivity of pancreatic cancer via UV radiation resistance-associated gene.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017, Volume: 122, Issue:3

    Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Cell Line, Tumor; DNA Repair; Early Gr

2017
No association between metformin use and survival in patients with pancreatic cancer: An observational cohort study.
    Medicine, 2017, Volume: 96, Issue:10

    Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metfo

2017
Metformin induces apoptosis of pancreatic cancer cells.
    World journal of gastroenterology, 2008, Dec-21, Volume: 14, Issue:47

    Topics: Adenocarcinoma; Apoptosis; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; C

2008
Metformin induces apoptosis of pancreatic cancer cells.
    World journal of gastroenterology, 2008, Dec-21, Volume: 14, Issue:47

    Topics: Adenocarcinoma; Apoptosis; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; C

2008
Metformin induces apoptosis of pancreatic cancer cells.
    World journal of gastroenterology, 2008, Dec-21, Volume: 14, Issue:47

    Topics: Adenocarcinoma; Apoptosis; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; C

2008
Metformin induces apoptosis of pancreatic cancer cells.
    World journal of gastroenterology, 2008, Dec-21, Volume: 14, Issue:47

    Topics: Adenocarcinoma; Apoptosis; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; C

2008
Antidiabetic therapies affect risk of pancreatic cancer.
    Gastroenterology, 2009, Volume: 137, Issue:2

    Topics: Adenocarcinoma; Age Distribution; Aged; Cancer Care Facilities; Case-Control Studies; Causality; Com

2009
Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth.
    Cancer research, 2009, Aug-15, Volume: 69, Issue:16

    Topics: Animals; Calcium; Carcinoma, Pancreatic Ductal; Cell Proliferation; DNA Replication; Down-Regulation

2009
Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, May-01, Volume: 16, Issue:9

    Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Mechanist

2010
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.
    Journal of cellular and molecular medicine, 2011, Volume: 15, Issue:4

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resi

2011
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Sep-01, Volume: 16, Issue:17

    Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Genetic Predisposition to Diseas

2010
Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals.
    BMC cancer, 2011, Jan-18, Volume: 11

    Topics: Adult; Aged; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; I

2011
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
    Cancer prevention research (Philadelphia, Pa.), 2012, Volume: 5, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Ce

2012
Diabetes and pancreatic cancer.
    Molecular carcinogenesis, 2012, Volume: 51, Issue:1

    Topics: Adipokines; Diabetes Mellitus, Type 2; Early Detection of Cancer; Humans; Hypoglycemic Agents; Insul

2012
A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells.
    Oncology reports, 2012, Volume: 27, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2012
Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells.
    Diabetes research and clinical practice, 2012, Volume: 96, Issue:2

    Topics: Animals; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Metformin; Mice;

2012
Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis.
    The American journal of gastroenterology, 2012, Volume: 107, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus; Female; Humans; Hypoglycemi

2012
Metformin and cancer stem cells: old drug, new targets.
    Cancer prevention research (Philadelphia, Pa.), 2012, Volume: 5, Issue:3

    Topics: Animals; Cell Movement; Cell Proliferation; Female; Humans; Hypoglycemic Agents; Metformin; MicroRNA

2012
Metformin and pancreatic cancer: a clue requiring investigation.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, May-15, Volume: 18, Issue:10

    Topics: Antineoplastic Agents; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metfo

2012
Metformin use is associated with better survival of diabetic patients with pancreatic cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, May-15, Volume: 18, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypoglyce

2012
Illuminating the diabetes-cancer link.
    Journal of the National Cancer Institute, 2012, Jul-18, Volume: 104, Issue:14

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Glucose; Breast Neoplasms; Clinical Trials as Topic

2012
Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK.
    Biochemical and biophysical research communications, 2013, Jan-04, Volume: 430, Issue:1

    Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Repl

2013
Prevention of pancreatic cancer induction in hamsters by metformin.
    Gastroenterology, 2001, Volume: 120, Issue:5

    Topics: Adenocarcinoma; Animals; Cell Division; Cricetinae; Dietary Fats; DNA; Female; Glucose; Hypoglycemic

2001
chemdatabank.com